Mugdha Velankar

1.1k total citations · 1 hit paper
7 papers, 863 citations indexed

About

Mugdha Velankar is a scholar working on Molecular Biology, Hematology and Organic Chemistry. According to data from OpenAlex, Mugdha Velankar has authored 7 papers receiving a total of 863 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 5 papers in Hematology and 1 paper in Organic Chemistry. Recurrent topics in Mugdha Velankar's work include Multiple Myeloma Research and Treatments (5 papers), Cell death mechanisms and regulation (4 papers) and Ubiquitin and proteasome pathways (3 papers). Mugdha Velankar is often cited by papers focused on Multiple Myeloma Research and Treatments (5 papers), Cell death mechanisms and regulation (4 papers) and Ubiquitin and proteasome pathways (3 papers). Mugdha Velankar collaborates with scholars based in United States, Netherlands and Italy. Mugdha Velankar's co-authors include Kenneth C. Anderson, Teru Hideshima, Dharminder Chauhan, Paul G. Richardson, Klaus Podar, Nicholas Mitsiades, Constantine S. Mitsiades, Saskia Neuteboom, Michael A. Palladino and Anthony Letai and has published in prestigious journals such as Blood, Cancer Cell and Oncogene.

In The Last Decade

Mugdha Velankar

7 papers receiving 823 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

2005 560 citations Dharminder Chauhan, Laurence Catley et al. Cancer Cell profile →

Peers

Countries citing papers authored by Mugdha Velankar

Since Specialization

Citations

This map shows the geographic impact of Mugdha Velankar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mugdha Velankar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mugdha Velankar more than expected).

Fields of papers citing papers by Mugdha Velankar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mugdha Velankar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mugdha Velankar. The network helps show where Mugdha Velankar may publish in the future.

Co-authorship network of co-authors of Mugdha Velankar

This figure shows the co-authorship network connecting the top 25 collaborators of Mugdha Velankar. A scholar is included among the top collaborators of Mugdha Velankar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mugdha Velankar. Mugdha Velankar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

#	Work	Indexed citations
1	Hematopathology 2009 ·Modern Pathology ·Ilan Weinreb, Bayardo Perez‐Ordoñez, Runjan Chetty, Irving Dardick, (unknown), Jennifer L. Hunt, (unknown), Annjanette Stone, Conghua Xie, Steven A. Schichman, (unknown), Serhan Alkan, (unknown), (unknown), Mugdha Velankar, Süheyla Bozkurt, (unknown), Afshin Maleki, Rolando García	1
2	A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma 2006 ·Oncogene ·Dharminder Chauhan, Mugdha Velankar, Mohan Brahmandam, Teru Hideshima, Klaus Podar, Paul G. Richardson, R Schlossman, Irene M. Ghobrial, Noopur Raje, Nikhil C. Munshi, Kenneth C. Anderson	183
3	Distinct Dynamic Profiles for NPI-0052-And Bortezomib-Induced Apoptosis in Multiple Myeloma. 2006 ·Blood ·Dharminder Chauhan, Ajita Singh, Mugdha Velankar, Teru Hideshima, Huib Ovaa, Celia R. Berkers, Giada Bianchi, Roberto Sitia, Nikhil C. Munshi, Paul G. Richardson, Michael A. Palladino, Kenneth C. Anderson	2
4	Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM) 2006 ·Blood ·Dharminder Chauhan, Paola Neri, Mugdha Velankar, Klaus Podar, Teru Hideshima, Mariateresa Fulciniti, Pierfrancesco Tassone, Noopur Raje, Constantine S. Mitsiades, Nicholas Mitsiades, Paul G. Richardson, Leigh Zawel, Mary Tran, Nikhil C. Munshi, Kenneth C. Anderson	111
5	A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib breakdown → 2005 ·Cancer Cell ·Dharminder Chauhan, Laurence Catley, Guilan Li, Klaus Podar, Teru Hideshima, Mugdha Velankar, Constantine S. Mitsiades, Nicholas Mitsiades, Hiroshi Yasui, Anthony Letai, Huib Ovaa, Celia R. Berkers, Benjamin Nicholson, Ta‐Hsiang Chao, Saskia Neuteboom, Paul G. Richardson, Michael A. Palladino, Kenneth C. Anderson	560
6	Targeting Bcl-2 as Therapy for Multiple Myeloma. 2005 ·Blood ·Dharminder Chauhan, Mugdha Velankar, Teru Hideshima, Constantine S. Mitsiades, Laurence Catley, Noopur Raje, Robert Schlossman, Paul G. Richardson, Kenneth C. Anderson	5
7	Requirement of Caspase-8 Versus Caspase-9 during Apoptosis in Multiple Myeloma Cells Induced by Bortezomib- or a Novel Proteasome Inhibitor NPI-0052. 2005 ·Blood ·Dharminder Chauhan, Laurence Catley, Mugdha Velankar, Anthony Letai, Teru Hideshima, Klaus Podar, Hiroshi Yasui, Nicholas Mitsiades, Constantine S. Mitsiades, Yu‐Tzu Tai, Noopur Raje, Nikhil C. Munshi, Michael A. Palladino, Kenneth C. Anderson	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact